-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicycle Therapeutics Outlines 2026 Strategy With Duravelo-2 Regulatory Update Expected In 1Q 2026, Radiopharmaceutical Data In 2026, And Runway Into 2028

Benzinga·01/12/2026 12:40:42
Listen to the news
  • Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies
  • Emerging radiopharmaceuticals pipeline progressing, with additional EphA2 human imaging data planned for the first half of 2026
  • Initial data for Phase 1/2 Duravelo-3 trial exploring zelenectide pevedotin in NECTIN4 amplified breast cancer expected in the second half of 2026
  • Expected financial runway into 2028 to support execution of clinical and strategic priorities